USPTO 2015–2025 USPTO PatentsView US Corporation

Berkshire Biomedical Corporation

USPTO PatentsView assignee record - 12 granted patents across 7 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).

12
Total patents granted
7
CPC technology areas
21.8
Avg claims per patent
+100%
5-year filing velocity

The verdict

Berkshire holds 12 US patents across 7 technology areas, rank #22,292 of 50,000 tracked assignees.

#22,292
of 50,000 US assignees by volume
Top 50%
by Innovation Score (35.3/100)
21.8
avg claims per patent
+100%
filing velocity, last 5 yrs

Portfolio overview

Berkshire Biomedical Corporation has been granted 12 US utility patents between 2017 and 2025, placing Berkshire Biomedical Corporation at rank #22,292 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.8 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, Berkshire Biomedical Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 35.3/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 8 grants, compared with 4 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Berkshire Biomedical Corporation's 21.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Berkshire Biomedical Corporation against peers pursuing similar technology classes.

How does Berkshire compare?

Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀

patents

What this shows Berkshire holds 12 patents, placing it at rank #22,292 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Berkshire's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

0.511.522.5 20172018201920202021202220242025 2
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Berkshire Biomedical Corporation patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 8.3%
2018 1 8.3%
2019 2 16.7%
2020 2 16.7%
2021 1 8.3%
2022 1 8.3%
2024 2 16.7%
2025 2 16.7%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#22,292

Across all tracked assignees

Innovation Score

35.3 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Berkshire Biomedical Corporation hold?
Berkshire Biomedical Corporation holds 12 US granted patents filed between 2017 and 2025, spanning 7 technology areas.
What is Berkshire Biomedical Corporation's Innovation Score?
Berkshire Biomedical Corporation has an Innovation Score of 35.3 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Berkshire Biomedical Corporation focus on?
Berkshire Biomedical Corporation's top technology area is G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA) with 8 patents. The company has filed patents in 7 CPC subclasses total.
Is Berkshire Biomedical Corporation's patent filing rate increasing or decreasing?
Berkshire Biomedical Corporation's recent filing velocity is +100% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Berkshire Biomedical Corporation's patents?
Berkshire Biomedical Corporation's patents average 21.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Berkshire Biomedical Corporation patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Guides to patent portfolio analysis

How to use this portfolio

Berkshire's 12 grants land it in the top 50% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Berkshire ranks #22,292 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in G16H - see who else leads that technology area. G16H leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.